1 results found.

Recurrent Squamous Cell Carcinoma of the Nasopharynx, or Stage IV Clinical Trial using Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis